More than a year after biotech stock indices peaked, the markets are worse than ever. Meanwhile, rumors of an impending wave of opportunistic biotech acquisitions are yet to materialize. Labiotech interviewed Managing Partner Sander Slootweg for insights on the current state of biotech.